New drug cocktail aims to shrink advanced stomach tumors
NCT ID NCT05041153
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that has spread or cannot be removed by surgery. The study will enroll 15 participants who have already received prior treatment. The main goal is to see how many patients respond to the combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab and lenvatinib
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced stomach cancer that has not responded to prior therapy.
- What could go wrong
- This is a very early, small pilot study with only 15 participants. It is designed mainly to check safety and early signs of effectiveness, so success is far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Experimental drug combo targets Hard-to-Treat GI cancers
- New drug cocktail aims to tackle Hard-to-Treat stomach cancer
- New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
- Home monitoring may keep cancer patients out of the ER
- New drug cocktail shows promise for tough stomach cancers